Cargando…

Evaluation of Global Hemostatic Assays in Response to Factor VIII Inhibitors

Global hemostatic assays including thromboelastography (TEG), Innovance ETP (endogenous thrombin potential), and Thrombinoscope could measure thrombin generation potential and be useful to guide management of patients with factor VIII (FVIII) inhibitors. However, the performance characteristics of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Ping, Jani, Jayesh, Streiff, Michael B., Zheng, Gang, Kickler, Thomas S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714898/ https://www.ncbi.nlm.nih.gov/pubmed/30880432 http://dx.doi.org/10.1177/1076029619836171

Ejemplares similares

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
por: Abt, Nicholas B., et al.
Publicado: (2014)

Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX
por: Yoo, Ki-Young, et al.
Publicado: (2018)

Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations
por: Duarte, Rita Carolina Figueiredo, et al.
Publicado: (2017)

Acquired Factor VIII Inhibitors: Three Cases
por: Kyaw, Tay Za, et al.
Publicado: (2013)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
por: Karakuş, Volkan, et al.
Publicado: (2012)

Repression of Factor VIII Inhibitor Development with Apoptotic Factor VIII-expressing Embryonic Stem Cells
por: Sakurai, Yoshihiko, et al.
Publicado: (2013)

Viscoelastic Hemostatic Assays for Postpartum Hemorrhage
por: Liew-Spilger, Alyson E., et al.
Publicado: (2021)

Impact of different factor VIII inhibitor kinetic profiles on the inhibitor titer quantification using the modified Nijmegen–Bethesda assay
por: Ketteler, Carolin, et al.
Publicado: (2022)

Upregulation of pulmonary tissue factor, loss of thrombomodulin and immunothrombosis in SARS-CoV-2 infection
por: Francischetti, Ivo M.B., et al.
Publicado: (2021)

Viscoelastic Hemostatic Assays for Orthopedic Trauma and Elective Procedures
por: Mamczak, Christiaan N., et al.
Publicado: (2022)

Utility of viscoelastic hemostatic assay to guide hemostatic resuscitation in trauma patients: a systematic review
por: Zhu, Zhe, et al.
Publicado: (2022)

Different impact of factor VIII products on inhibitor development?
por: van den Berg, H. Marijke
Publicado: (2016)

FACTOR VIII COAGULANT ACTIVITY AND FACTOR VIII-LIKE ANTIGEN: INDEPENDENT MOLECULAR ENTITIES
por: Zimmerman, Theodore S., et al.
Publicado: (1973)

Monitoring of different factor VIII replacement products using a factor VIII one‐stage clotting assay on cobas t 511/711 analysers
por: Ketteler, Carolin, et al.
Publicado: (2021)

Factor VIII antibody immune complexes modulate the humoral response to factor VIII in an epitope-dependent manner
por: Batsuli, Glaivy, et al.
Publicado: (2023)

Multicenter performance evaluation and reference range determination of a new one‐stage factor VIII assay
por: Lowe, Anna E., et al.
Publicado: (2022)

“Antihemophilic factor is not the only answer for all factor VIII deficiencies.” Case report of odontogenic infection in a patient with hemophilia A, complicated by factor VIII inhibitors, and managed by transfusion of antihemophilic factor and factor VIII inhibitor bypass activity
por: Sudheesh, K. M., et al.
Publicado: (2016)

Efficacy of the hemostatic device VasoSTAT and the study of hemostatic factor
por: Naganawa, Hirokazu, et al.
Publicado: (2021)

Acquired Factor VIII Inhibitor Presenting as Occult GI Bleeding
por: Pacheco Cano, Carlos I., et al.
Publicado: (2018)

Concomitant factor VIII inhibitor and lupus anticoagulant in an asymptomatic patient
por: Jacobs, Jeremy W., et al.
Publicado: (2021)

Management of Acquired Factor VIII Inhibitors With NovoSeven and Obizur
por: Miatech, Jennifer L, et al.
Publicado: (2021)

Acquired factor VIII inhibitor caused by solid tumor malignancy
por: de Bear, Olivia, et al.
Publicado: (2023)

Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII‐treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2021)

Viscoelastic Hemostatic Assays: A Primer on Legacy and New Generation Devices
por: Volod, Oksana, et al.
Publicado: (2022)

A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy
por: Chen, Alex C., et al.
Publicado: (2020)

Acquired factor VIII inhibitor syndrome: A rare cause of hematuria
por: Kannan, Muthuvel Seral, et al.
Publicado: (2015)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

PB2655: EVALUATION OF THE EFFICACY AND SAFETY IMMUNOSUPPRESSIVE THERAPY IN PATIENTS WITH ACQUIRED FACTOR VIII AND IX INHIBITOR
por: Koyun, Derya, et al.
Publicado: (2023)

Acquired Factor VIII Inhibitor in a Patient of Rheumatoid Arthritis on Tumor Necrosis Factor Inhibitor Therapy
por: Mori, Tomoyo, et al.
Publicado: (2018)

Factor VIII companion diagnostic for haemophilia
por: Hu, Chunxiao, et al.
Publicado: (2022)

Evaluation of Factor VIII as a Risk Factor in Indian Patients with DVT
por: Hazra, Darpanarayan, et al.
Publicado: (2015)

Verification and Comparison of Chromogenic Factor VIII Activity Assays in Patients With Hemophilia Treated With and Without Emicizumab
por: Lee, Min Young, et al.
Publicado: (2023)

Hemostatic protocol and risk-reduction surgery for treating coronary artery disease with aortic stenosis in a patient with combined coagulation factor VIII and XI deficiency: a case report
por: Honda, Sayaka, et al.
Publicado: (2023)

Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections
por: Zanetto, Alberto, et al.
Publicado: (2022)

Sensitive Measurement of Clinically Relevant Factor VIII Levels in Thrombin Generation Assays Requires Presence of Factor XIa
por: van de Berg, Tom W., et al.
Publicado: (2023)

Viscoelastic Hemostatic Assays and Platelet Function Testing in Patients with Atherosclerotic Vascular Diseases
por: Samoš, Matej, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
por: Schmitt, Christophe, et al.
Publicado: (2021)

Platelet Function and Factor VIII in Uremia(*)
por: Park, Hee Sook, et al.
Publicado: (1987)

Tolerating Factor VIII: Recent Progress
por: Lacroix-Desmazes, Sebastien, et al.
Publicado: (2020)

Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIII
por: Grushin, K, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_lb0s1f9q7rtdpulmsr9rgikij3